BrainCool AB (publ): Breakthrough for IQool™ System on the US market

BrainCool AB (publ) has received an order for two (2) IQool™ Systems from a clinic in the state of Pennsylvania, USA.

The order, amounting to half a million Swedish kronor, represents a major step for operations in the United States.

IQool™ System was selected over the main competitor and it is the first order received without prior evaluation of the product.

CEO Martin Waleij comments;

-        The order is a clear signal that the IQool™ concept and its clear benefits are accepted by the market. The clinic in Pennsylvania has also conducted a “trade-in” and is discarding the competitor’s products, meaning now only BrainCool's products will be used in clinical practice.

This information is information that BrainCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on October 30, 2019. 

For more information

Martin Waleij - CEO                                                               
+46 - 733 -93 70 76                                                                                          
E-mail: martin.waleij@braincool.se                       

About BrainCool AB (publ)

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.